The Waldenstrom macroglobulinemia market is witnessing steady growth driven by advances in targeted therapies, particularly BTK inhibitors like IMBRUVICA and BRUKINSA. Rising awareness, improved ...

Collection of ethnicity data in clinical research has been poor historically, but is essential to ensure that interventions are effective and safe across diverse populations. These data are needed to ...

Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...

DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...

StudyFormycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 10.07.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Italy’s Robin Foà, MD, an iconic European clinician-researcher, has been at forefront of hematology’s transformation for half ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region, Chris Round, outlines what practical steps the company is taking to improve life for patients ...

Merck will continue to step up for patients, taking a more impact-orientated approach to work with them, their carers and patient advocacy groups.

Dow, S&P500 hold gains as traders weigh Trump’s tariffs, Fed’s path. Watch Starbucks, Verona, AES as sector shifts create ...